Latest News on GILD

Financial News Based On Company


Advertisement
Advertisement

Manny Rodriguez of Gilead Sciences to be Recognized as One of the Visionaries of 2027 in Miami

https://www.noticiasnewswire.com/manny-rodriguez-of-gilead-sciences-to-be-recognized/
Manny Rodriguez, Director of HIV Public Affairs Communications at Gilead Sciences, will be honored as one of the Visionaries of 2027 in Miami for his leadership in developing culturally relevant communication strategies for HIV education and prevention, particularly among Latino communities. His work aims to reduce stigma and improve access to health information and care. Gilead Sciences has invested significantly in Latino community organizations to address disparities in HIV prevention and care.

Gilead Sciences Inc. stock outperforms competitors despite losses on the day

https://www.marketwatch.com/data-news/gilead-sciences-inc-stock-outperforms-competitors-despite-losses-on-the-day-9ca18775-c81d1c587273?mod=goog_fin_scmw
Gilead Sciences Inc. (GILD) shares declined by 1.45% to $166.53 on Thursday, experiencing its second consecutive day of losses. This occurred during a broad market downturn, with the S&P 500 Index (SPX) falling 2.02% and the Dow Jones Industrial Average (DJIA) dropping 2.19%. Despite the individual stock loss, the headline indicates it still outperformed competitors.

Gilead Partnership Helps Provide Support for PBC Caregivers

https://www.gilead.com/stories/gilead-partnership-helps-provide-support-for-pbc-caregivers
Gilead has partnered with Calm® to provide mental well-being resources at no cost for individuals living with primary biliary cholangitis (PBC) and their loved ones. This initiative aims to raise awareness of the daily impact of PBC, a rare liver disease, on patients and their caregivers, who often face unseen challenges like chronic fatigue, severe itch, and emotional strain. The partnership was highlighted at The Liver Meeting®, where caregiver Mario shared his experience, emphasizing the critical need for community and mental health support.

1,321,457 Gilead Sciences, Inc. $GILD Shares Sold by Voya Investment Management LLC

https://www.marketbeat.com/instant-alerts/filing-1321457-gilead-sciences-inc-gild-shares-sold-by-voya-investment-management-llc-2026-11-19/
Voya Investment Management LLC significantly reduced its stake in Gilead Sciences, selling over 1.3 million shares and retaining about $78.1 million worth of stock. This comes as Gilead reported strong third-quarter earnings, beating analyst estimates for both EPS and revenue, and declared a quarterly dividend of $0.82 per share. The article also details other institutional investor activity, insider transactions, and recent analyst ratings for GILD.

Gilead Sciences, Inc. $GILD Shares Purchased by Boston Partners

https://www.marketbeat.com/instant-alerts/filing-gilead-sciences-inc-gild-shares-purchased-by-boston-partners-2026-11-19/
Boston Partners significantly increased its stake in Gilead Sciences by 8.4% in the third quarter, holding approximately 6.52 million shares valued at about $970 million. This comes as Gilead reported strong quarterly earnings of $2.55 per share and revenue of $8.30 billion, both exceeding analyst expectations. The biopharmaceutical company also declared a quarterly dividend of $0.82 per share.
Advertisement

With over 14M rights outstanding under other employee plans, Lakefront (LKFT) creates more under a new plan.

https://www.stocktitan.net/sec-filings/LKFT/6-k-lakefront-biotherapeutics-nv-current-report-foreign-issuer-1ac099246315.html
Lakefront Biotherapeutics NV (LKFT) has created 150,000 new subscription rights under a "Subscription Right Plan November 2026" for current and potential employees. Each right allows subscription to one new Lakefront share. This new plan adds to the existing 14,197,983 subscription rights already outstanding under other employee plans, and a separate right for Gilead Therapeutics to reach a 29.9% ownership stake.

Caught Out By Arcus Biosciences' Slide? Here's What Bears Saw

https://sg.finance.yahoo.com/news/caught-arcus-biosciences-slide-heres-201121538.html
Arcus Biosciences experienced a 29.6% loss for shareholders since the start of the year, despite promising kidney cancer data and a long cash runway. Investors weighed optimistic outlooks, predicting a 19% increase in Fair Value based on drug development and funding, against cautious views highlighting reliance on partnerships and regulatory risks, which suggested a 50% decrease in Fair Value. The company's recent performance showed mixed signals, with collaboration revenue dropping and Gilead opting out of a partnership payment, leaving profitability hopes unproven.

Suffolk taps array of contech applications on Gilead’s new California research center

https://www.constructiondive.com/news/suffolk-gilead-lab-contech-california-construction/875068/
Suffolk Construction leveraged various technology solutions, including OpenSpace, Dusty Robotics, Kaya AI, and Alice Technologies, to complete Gilead Sciences' new $847 million research center in Foster City, California. The project emphasizes adaptability with features like movable interior panels and additional utility connections to support Gilead's evolving scientific needs. This initiative aligns with Suffolk's broader strategy of adopting advanced construction technology through its Jobsites of the Future program and Suffolk Technologies investment arm.

NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox (Monkeypox)

https://finance.yahoo.com/healthcare/articles/nanoviricides-inc-filed-quarterly-report-134500597.html
NanoViricides, Inc. has announced the filing of its Quarterly Report, highlighting that its broad-spectrum antiviral drug, NV-387 Oral Gummies, has entered two Phase II clinical trials. One trial is for the treatment of Ebola Bundibugyo Virus Disease, for which there is currently no licensed drug or vaccine, and the other is for Mpox (Monkeypox). The company also reported significant progress in its Measles drug program, receiving Orphan Drug and Rare Pediatric Disease Drug designations for NV-387, and detailed its financial position and future funding needs for advancing its clinical development pipeline.

Gilead Sciences Cancer Research Center: Suffolk Completes 182,000-Square-Foot Foster City Facility

https://constructionreviewonline.com/gilead-sciences-cancer-research-center-suffolk-completes-182000-square-foot-foster-city-facility/
Suffolk has announced the completion of Gilead Sciences' new 182,000-square-foot Cancer Research Center in Foster City, California. This five-story facility features flexible labs that can be reconfigured without demolition, designed to evolve with Gilead's research needs. Suffolk utilized advanced construction technologies like Dusty Robotics, ALICE Technologies, and OpenSpace to enhance precision and coordination during the project.
Advertisement

Gilead Sciences chief comm & corp aff officer Mercier sells $4.7M shares

https://www.investing.com/news/insider-trading-news/gilead-sciences-chief-comm--corp-aff-officer-mercier-sells-47m-shares-93CH-5034542
Johanna Mercier, Chief Communications & Corporate Affairs Officer at Gilead Sciences, sold 28,000 shares worth $4.7 million on November 16, 2026, as part of a pre-arranged trading plan. On the same day, she also acquired 25,000 shares by exercising stock options for $1.8 million. The company has a market capitalization of $211 billion and has consistently raised its dividend for 12 years.

Form 4 Gilead Sciences Inc: Johanna Mercier (Chief Comm & Corp Aff Officer) For: 16 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-gilead-sciences-inc-johanna-mercier-chief-comm--corp-aff-officer-for-16-november-93CH-5711250
This article reports on a Form 4 filing for Gilead Sciences Inc. The filing concerns Johanna Mercier, Chief Commercial and Corporate Affairs Officer, and is dated November 16. The content provides basic information about the SEC filing.

Form 4 Gilead Sciences Inc: Andrew D. Dickinson (CFO) For: 16 November

https://ca.investing.com/news/stock-market-news/form-4-gilead-sciences-inc-andrew-d-dickinson-cfo-for-16-november-93CH-4965512
This article reports on a Form 4 filing for Gilead Sciences Inc., detailing a transaction involving Andrew D. Dickinson, the company's CFO, on November 16. The brief notice highlights insider trading activity for the pharmaceutical company.

Gilead Sciences CFO Dickinson sells $514,410 in stock

https://www.investing.com/news/insider-trading-news/gilead-sciences-cfo-dickinson-sells-514410-in-stock-93CH-5034509
Andrew D. Dickinson, CFO of Gilead Sciences (NASDAQ:GILD), sold 3,000 shares of company stock for $514,410 on November 16, 2026. This transaction occurred while the stock was trading near its 52-week high, with InvestingPro analysis indicating it might be overvalued. The sale was part of a Rule 10b5-1 trading plan adopted in August 2024, leaving Dickinson with 158,096 directly held shares.

Gilead Sciences (GILD) officer exercises 25,000 options and sells 28,000 shares.

https://www.stocktitan.net/sec-filings/GILD/form-4-gilead-sciences-inc-insider-trading-activity-f29d0bbd7251.html
Johanna Mercier, Chief Comm & Corp Aff Officer at Gilead Sciences (GILD), exercised options to acquire 25,000 common shares and subsequently sold 28,000 shares on November 16, 2026. These transactions, executed under a Rule 10b5-1 trading plan, involved sale prices ranging from $169.57 to $171.69. Following these activities, Mercier's reported option position was 44,960 options and her common stock holdings decreased from 113,684 to 110,684 shares.
Advertisement

Gilead Sciences (GILD) executive Mercier sold 28,000 shares for $4.78M at an average $170.55 under a 10b5-1 plan

https://www.quantisnow.com/insight/chief-comm-corp-aff-officer-johanna-mercier-exercised-25000-shares-6797706
Gilead Sciences executive Johanna Mercier sold 28,000 shares of GILD for $4.78 million at an average price of $170.55, and acquired 25,000 shares at $72.34 on November 16, 2026, under a 10b5-1 trading plan adopted in February 2025. After these transactions, Mercier directly holds 110,684 shares. This insider activity and historical stock performance following GILD headlines are detailed in the report.

Julio Rodriguez Appointed Director of NPP HCP Marketing in US Oncology

https://oncodaily.com/career/julio-rodriguez-us-oncology-634383
Julio Rodriguez has been appointed Director of Non Personal Promotion (NPP) HCP Marketing in US Oncology at Gilead Sciences. In this new role, he will focus on advancing innovative HCP engagement and driving significant impact for customers and the business. Rodriguez's expertise includes omnichannel strategy, oncology brand engagement, cross-functional collaboration, and patient-centered digital transformation.

Natera Short Interest Rises As Bets Remain Near September Peak

https://www.benzinga.com/trading-ideas/short-ideas/26/11/63355238/natera-short-interest-rises-as-bets-remain-near-september-peak
Natera Inc. (NASDAQ:NTRA) saw its short interest rise by 3.77% to 6.07 million shares as of October 30, 2026, representing 4.31% of the float. This level is just below the September 30 peak of 6.36 million shares. The company's shares were down 3.22% at $279.18 on Tuesday, significantly below its 52-week high.

Gilead Sciences Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/gilead-sciences-inc-stock-outperforms-competitors-on-strong-trading-day-7b19aa72-79b18b5bd9c0?mod=goog_fin_scmw
Gilead Sciences Inc. (GILD) shares rose 1.60% to $170.26 on Tuesday, outperforming the broader market, which saw the S&P 500 Index and Dow Jones Industrial Average decline. The company's stock closed 3.58% below its 52-week high of $176.58, achieved earlier in November.

Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs

https://www.tradingview.com/news/marketbeat:f0b0cb10c094b:0-gilead-sciences-maps-growth-beyond-biktarvy-with-hiv-cancer-and-inflammation-drugs/
Gilead Sciences is focusing on HIV and oncology to drive growth through the current decade, while simultaneously developing an inflammation business for the 2030s. The company is diversifying its HIV treatment business ahead of the 2036 patent expiration for BIKTARVY and is also confident in its Tubulis antibody-drug conjugate platform for cancer. Additionally, Gilead plans to expand its inflammation portfolio with oral medicines, including potential monotherapies and combinations for inflammatory bowel disease.
Advertisement

Gilead at Jefferies Global Healthcare Conference: growth broadens

https://www.investing.com/news/transcripts/gilead-at-jefferies-global-healthcare-conference-growth-broadens-93CH-5033420
Gilead Sciences presented at the Jefferies Global Healthcare Conference, highlighting its strongest growth in over a decade driven by HIV, oncology, and inflammation. The company emphasized its rebuilt research organization, expanded pipeline with 10-12 internally generated compounds annually, and a long patent runway until BIKTARVY expires in 2036. Gilead also outlined its strategy for long-acting HIV treatments, the potential of its Tubulis ADC platform in oncology, and the promising future of oral inflammation drugs.

Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind

https://www.tradingview.com/news/marketbeat:a43bda867094b:0-gilead-sciences-bets-on-hiv-prevention-growth-despite-1-5-billion-biktarvy-headwind/
Gilead Sciences expects its HIV prevention portfolio and a potential new multiple myeloma cell therapy to drive growth, offsetting a projected $1.5 billion Biktarvy headwind in 2028. The company is seeing strong adoption of its twice-yearly HIV PrEP injection, Yeztugo, and anticipates a regulatory decision for a weekly oral version in February. Additionally, Gilead is awaiting a December 23 regulatory decision for anito-cel, a CAR T-cell therapy for multiple myeloma, which it expects to become a market leader.

Gilead Partners With Generic Manufacturers to Boost Future Access to Experimental Ebola Prevention Drug

https://www.benzinga.com/news/health-care/26/11/63343212/gilead-partners-with-generic-manufacturers-to-boost-future-access-to-experimental-ebola-prevention-drug
Gilead Sciences Inc. has signed royalty-free voluntary licensing agreements with three generic drugmakers—Dr. Reddy’s Laboratories, Eva Pharma, and Ferozsons Laboratories—to enhance future access to its experimental antiviral obeldesivir. This drug is intended for post-exposure prophylaxis against Ebola Bundibugyo virus disease in 127 low- and lower-middle-income nations, including all African countries affected by the current outbreak. Additionally, Gilead is expanding its existing remdesivir licenses to cover filovirus disease and has donated over 38,000 vials of remdesivir for outbreak preparedness and investigational use in affected regions.

Gilead Wins $69 Million Damages, Permanent Injunction Against Defaulting Defendants in HIV Counterfeiting Ring

https://ipwatchdog.com/2026/11/17/gilead-wins-69-million-damages-permanent-injunction-against-defaulting-defendants-in-hiv-counterfeiting-ring/
Gilead Sciences has been awarded over $69 million in damages and a permanent injunction against eight individuals and 18 shell companies involved in an HIV drug counterfeiting ring. The defendants acquired authentic Gilead prescription drug bottles, refilled them with other medications, resealed them with fake seals, and sold them with falsified chain-of-sale documents. U.S. District Judge Natasha Merle adopted a magistrate judge's recommendation, holding the defendants liable for federal trademark infringement and counterfeiting under the Lanham Act.

Johnson & Johnson to acquire Ollin Biosciences in deal worth up to $3.3 billion

https://www.ophthalmologytimes.com/view/johnson-johnson-to-acquire-ollin-biosciences-in-deal-worth-up-to-3-3-billion
Johnson & Johnson is set to acquire Ollin Biosciences for up to $3.3 billion, securing OLN324, a next-generation bispecific antibody for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). Blackstone Life Sciences will fund phase 3 development with $750 million. Early clinical data from the JADE trial indicate OLN324's potential for a transformative clinical profile, showing faster retinal drying and durable responses compared to faricimab.
Advertisement

Should You Invest in the VanEck Biotech ETF (BBH)?

https://sg.finance.yahoo.com/news/invest-vaneck-biotech-etf-bbh-102002689.html
The VanEck Biotech ETF (BBH), launched in December 2011, is a passively managed ETF offering broad exposure to the Healthcare - Biotech segment. With an expense ratio of 0.35% and $521.91 million in assets, it has returned 31.47% year-to-date. BBH holds a Zacks ETF Rank of 2 (Buy) and is considered a high-risk option due to its concentrated holdings.

Gilead signs licensing deals for Ebola drug obeldesivir

https://www.investing.com/news/company-news/gilead-signs-licensing-deals-for-ebola-drug-obeldesivir-93CH-5030919
Gilead Sciences Inc. has signed royalty-free voluntary licensing agreements with three generic manufacturers – Dr. Reddy’s Laboratories, Eva Pharma, and Ferozsons Laboratories – for its investigational antiviral obeldesivir. These agreements cover 127 low- and lower-middle-income countries, including those affected by the current Ebola Bundibugyo virus disease outbreak, aiming to facilitate manufacturing and supply while clinical trials are ongoing. Gilead is also updating existing remdesivir licenses to include filovirus disease and has donated over 38,000 vials of remdesivir for investigational use in affected regions, despite its efficacy against Ebola BVD not yet being established.

NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox (Monkeypox)

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/nanoviricides-inc.-has-filed-its-quarterly-report-broad-spectrum-anti-1252522
NanoViricides, Inc. has filed its Quarterly Report for the fiscal quarter ending September 30, 2026, announcing significant progress with its broad-spectrum antiviral drug NV-387. The drug, in oral gummy form, has entered two separate Phase II clinical trials: one for Ebola Bundibugyo Virus Disease and another for Mpox (Monkeypox). Additionally, NV-387 has received Orphan Drug and Rare Pediatric Disease Drug designations for Measles, with plans to advance it into a Phase II clinical trial for that indication next.

Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing

https://www.biospace.com/press-releases/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing
Gilead Sciences has signed royalty-free voluntary licensing agreements with three generic manufacturers (Dr. Reddy’s Laboratories, Eva Pharma, and Ferozsons Laboratories) to broaden access to its investigational antiviral, obeldesivir, for Ebola Bundibugyo virus disease (BVD) as post-exposure prophylaxis (PEP). These agreements cover 127 low- and lower-middle-income countries and are being implemented ahead of results from an ongoing Phase 3 trial. Additionally, Gilead is expanding existing voluntary licensing agreements for remdesivir to include filovirus disease, pending results from the WHO-sponsored PARTNERS trial for its use as a treatment for Ebola BVD.

Gilead signs generic licensing deals for experimental Ebola drug

https://www.reuters.com/legal/litigation/gilead-signs-generic-licensing-deals-experimental-ebola-drug-2026-11-16/
Gilead Sciences has signed royalty-free agreements with three generic drug manufacturers, Dr. Reddy's Laboratories, Eva Pharma, and Ferozsons Laboratories, to make its experimental Ebola prevention drug, obeldesivir, available in 127 low- and lower-middle-income countries. This move anticipates successful trial results and regulatory approvals for obeldesivir, which is currently in a late-stage trial for high-risk individuals and has shown activity against several Ebola-related viruses in preclinical studies. Gilead is also extending remdesivir licenses for Ebola-related diseases and has donated over 38,000 remdesivir vials to affected countries.
Advertisement

Europe approves the first once-daily pill for eligible adults with a chronic, painful skin disease.

https://www.stocktitan.net/news/INCY/povofortay-povorcitinib-approved-in-europe-as-the-first-once-daily-wtpdd3wpecar.html
The European Commission has approved Incyte's Povofortay (povorcitinib) as the first once-daily oral treatment for eligible adults with moderate to severe hidradenitis suppurativa (HS). This approval is based on Phase 3 STOP-HS1 and STOP-HS2 trials, which demonstrated the drug's efficacy and tolerability over 54 weeks. The U.S. Food and Drug Administration is also reviewing povorcitinib, with a potential approval and launch in the first quarter of 2027.

Gilead Sciences director Kelly Kramer sells $1.76 million in stock By Investing.com

https://in.investing.com/news/stock-market-news/gilead-sciences-director-kelly-kramer-sells-176-million-in-stock-93CH-5707928
Gilead Sciences director Kelly Kramer sold 10,376 shares of company stock worth approximately $1.76 million on November 12, 2026, after exercising non-qualified stock options. The transactions were executed under a pre-arranged trading plan, with shares sold at prices ranging from $168.2255 to $171.44. This sale occurs while Gilead's stock is trading near its 52-week high, and InvestingPro analysis suggests the stock is currently overvalued.

Gilead Sciences (GILD) director exercises options at $66.92 and sells 10,376 shares.

https://www.stocktitan.net/sec-filings/GILD/form-4-gilead-sciences-inc-insider-trading-activity-9d8cbb3b9055.html
Gilead Sciences, Inc. director Kelly A. Kramer exercised 10,376 non-qualified stock options at $66.92 per share on November 12, 2026. On the same day, Kramer sold all 10,376 acquired common shares in four separate transactions at prices ranging from $168.2255 to $171.44 per share. These transactions were conducted under a Rule 10b5-1 trading plan adopted on August 13, 2026.

Relmada names uro-oncology veteran as chief development officer

https://www.streetinsider.com/Management+Changes/Relmada+names+uro-oncology+veteran+as+chief+development+officer/27346559.html
Relmada Therapeutics, Inc. (Nasdaq: RLMD) has appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology. Dr. Jakobsen will lead clinical development, including the planned Phase 3 SPECTRUM program for NDV-01, a therapy for non-muscle invasive bladder cancer (NMIBC). His extensive experience at Ferring Pharmaceuticals and as a chief urologist is expected to be invaluable as Relmada prepares for the Phase 3 program.

Zacks Research Cuts Earnings Estimates for Gilead Sciences

https://www.marketbeat.com/instant-alerts/estimates-zacks-research-cuts-earnings-estimates-for-gilead-sciences-2026-11-16/
Zacks Research has lowered its FY2026 earnings estimate for Gilead Sciences to a loss of $0.86 per share, down from a prior estimate of a $0.65 loss, while maintaining a "Hold" rating. Despite this, Gilead recently beat Q3 earnings and revenue estimates, and the overall analyst consensus remains a "Moderate Buy" with an average target price of $171.07. Institutional investors have significantly increased their holdings in GILD, although some insider selling has also occurred.
Advertisement

Form 144 GILEAD SCIENCES For: 15 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-gilead-sciences-for-15-november-93CH-2808705
This article reports on the filing of Form 144 for Gilead Sciences (GILD) on November 15. Form 144 filings typically indicate an insider's intent to sell restricted or control securities. The brief announcement provides no further details beyond the company and date of the filing.

300,000 Gilead Sciences, Inc. $GILD Shares Sold by Migdal Insurance & Financial Holdings Ltd.

https://www.marketbeat.com/instant-alerts/filing-300000-gilead-sciences-inc-gild-shares-sold-by-migdal-insurance-financial-holdings-ltd-2026-11-15/
Migdal Insurance & Financial Holdings Ltd. significantly reduced its stake in Gilead Sciences by selling 300,000 shares, cutting its holdings by 49.7% in the third quarter. Despite this, other institutional investors like BlackRock Inc. and State Street Corp increased their positions. Gilead Sciences reported strong quarterly earnings of $2.55 per share and revenue of $8.30 billion, exceeding analyst estimates, and declared a quarterly dividend of $0.82 per share.

Gilead Beat the S&P 500 by More Than 25 Points in the Past Year, but $1,000 From a Decade Ago Is Still Worth Less Than $3,500

https://247wallst.com/investing/2026/11/15/gilead-beat-the-sp-500-by-more-than-25-points-in-the-past-year-but-1000-from-a-decade-ago-is-still-worth-less-than-3500/
Gilead Sciences (GILD) outperformed the S&P 500 by over 25 percentage points in the past year, returning 37.56% compared to the S&P 500's 12.25%. This strong performance was largely driven by a significant increase in HIV prevention sales, particularly from its drug Yeztugo. Despite recent success, Gilead's stock still lags the S&P 500 over a ten-year period; a $1,000 investment a decade ago would be worth $3,249 with dividends reinvested, versus $4,011 for the index.

Immunic Inc (IMUX) Stock Price, Quote, News & History

https://www.benzinga.com/quote/IMUX
This Benzinga article provides a comprehensive overview of Immunic Inc (IMUX) stock, including its current price, news, key data, and analyst ratings. As of November 13, 2026, IMUX was trading at $7.52, with recent news highlighting the appointment of Erik Lundgren as CEO and a new Medical Officer. The company is a clinical-stage biopharmaceutical firm focusing on oral immunology therapies for chronic inflammatory and autoimmune diseases.

Cellectis will shed 70% of workforce as part of in vivo pivot

https://www.fiercebiotech.com/biotech/cellectis-will-shed-70-workforce-part-vivo-pivot
Cellectis is undergoing a major pivot from allogeneic CAR-T therapies to in vivo gene editing candidates, which will result in a 70% reduction of its global workforce by 2027. The company scrapped its clinical-stage CAR-T programs due to a changing commercial and clinical landscape and is now focusing on two preclinical in vivo candidates, HEAL-101 and HEAL-201, with clinical trials expected to begin in China in 2027 and 2028, respectively. This strategic shift aligns with a broader industry trend among cell therapy companies and Big Pharma towards in vivo approaches.
Advertisement

Why Is Vir Biotechnology Stock Falling Friday?

https://www.benzinga.com/markets/offerings/26/11/63236510/why-is-vir-biotechnology-stock-falling-friday
Vir Biotechnology's stock fell in Friday's premarket trading after the company announced a $150 million public stock offering at $10 per share, raising concerns about shareholder dilution. Despite this short-term bearish pressure, the company has reported positive Phase 3 results for its hepatitis delta combination treatment and received FDA Fast Track designation for a prostate cancer candidate, with analysts maintaining a consensus Buy rating. The stock has seen significant gains over the past year, reflecting a mixed technical outlook.

3,183,169 Merck & Co., Inc. $MRK Shares Bought by Fisher Asset Management LLC

https://www.marketbeat.com/instant-alerts/filing-3183169-merck-co-inc-mrk-shares-bought-by-fisher-asset-management-llc-2026-11-13/
Fisher Asset Management LLC increased its stake in Merck & Co., Inc. (NYSE:MRK) by 8.3% during the third quarter, acquiring an additional 3,183,169 shares, bringing its total holding to 41.7 million shares valued at approximately $6.06 billion. Other major institutional investors also added to their Merck holdings, with institutional investors and hedge funds collectively owning 76.07% of the company's stock. Merck recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $155.74.

Gilead Sciences Inc. stock underperforms Thursday when compared to competitors

https://www.marketwatch.com/data-news/gilead-sciences-inc-stock-underperforms-thursday-when-compared-to-competitors-0b735efd-f45d8f3663ab?mod=goog_fin_scmw
Gilead Sciences Inc. (GILD) shares fell 1.05% on Thursday, closing at $167.95, while the broader market indices, including the S&P 500 and Dow Jones Industrial Average, also experienced losses. This marks the second consecutive day of declines for the stock. The article highlights Gilead's underperformance relative to its competitors on a generally negative trading day.

Compugen Ltd (CGEN) Q3 2026 Earnings Call Highlights: Revenue Doubles as Gilead and AstraZeneca ...

https://ca.finance.yahoo.com/news/compugen-ltd-cgen-q3-2026-230328346.html
Compugen Ltd (CGEN) reported a doubling of revenue to $3.8 million in Q3 2026, driven by payments from its Gilead license agreement, while reducing its net loss to $5.8 million. The company's cash position of $117.5 million is expected to fund operations into 2029, and it anticipates over $1 billion in future milestone payments and royalties from partnerships with AstraZeneca and Gilead. Key clinical trials for COM701 and partnered programs are progressing, with significant data readouts expected by Q1 2027 and H2 2027, respectively.

Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates

https://www.manilatimes.net/2026/11/13/tmt-newswire/globenewswire/assembly-biosciences-reports-third-quarter-2026-financial-results-and-recent-updates/2468993
Assembly Biosciences (Nasdaq: ASMB) reported its third quarter 2026 financial results, highlighting the initiation of a Phase 2 study for ABI-6250 in chronic hepatitis delta virus infection and the exercise of a 40% U.S. profit-share option for the HSV helicase primase inhibitor program with Gilead. The company also received a $75 million collaboration extension fee from Gilead, extending its cash runway into 2029. These advancements underscore Assembly Bio's progress in developing therapeutics for viral and liver diseases, with further Phase 2 studies anticipated for its liver disease programs and Gilead's GS-1179.
Advertisement

An experimental hepatitis D drug enters a mid-stage study; another liver trial is planned for early 2027.

https://www.stocktitan.net/news/ASMB/assembly-biosciences-reports-third-quarter-2026-financial-results-6pt5mkqwes2v.html
Assembly Biosciences reported a Q3 2026 net loss of $20.3 million while advancing its liver disease and herpes programs. The company initiated a Phase 2 study for ABI-6250 in chronic hepatitis delta and anticipates starting a cholestatic liver disease study in Q1 2027. A $75 million collaboration extension fee from Gilead is expected to fund operations into 2029.

Revenue falls 65% as MacroGenics (MGNX) swings from profit to a quarterly loss.

https://www.stocktitan.net/sec-filings/MGNX/10-q-macrogenics-inc-quarterly-earnings-report-18aba938f96f.html
MacroGenics (MGNX) reported a significant financial shift in Q3 2026, posting a $20.1 million net loss compared to a $16.8 million net income in the prior year, with total revenue decreasing by 65% to $18.7 million. This downturn is largely attributed to the completed sale of its CDMO operations, although the company recognized an $87.5 million net gain from the sale and aims to focus resources on its preclinical and clinical-stage pipeline. Despite the loss, the company's nine-month royalty revenue increased substantially due to higher ZYNYZ sales, and management believes current resources, partner payments, and cost savings will support operations through 2028.

MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress

https://www.stocktitan.net/news/MGNX/macro-genics-reports-third-quarter-2026-financial-results-and-ynluvzc0z5ha.html
MacroGenics (MGNX) reported third-quarter 2026 revenue of $18.667 million, a decrease from the prior year, and a net loss of $20.076 million. Despite the financial decline, the company highlighted progress in its cancer pipeline, including completed Phase 1 dose escalation for MGC028 and the initiation of Phase 1 dosing for MGC030. MacroGenics strengthened its cash position to $287.680 million and anticipates this, along with partner payments, will support operations through 2028.

Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?

https://www.theglobeandmail.com/investing/markets/stocks/MRK/pressreleases/8807259/can-gilead-sciences-hiv-business-fuel-sustainable-long-term-growth/
Gilead Sciences' HIV business, led by Biktarvy and Descovy, continues to show strong momentum, with the company raising its 2026 HIV sales growth projection to 12%. New therapies like the injectable Yeztugo are becoming key growth drivers, and a robust pipeline, including potential once-weekly oral and long-acting injectable treatments, is expected to further expand future growth opportunities. Despite competition from GSK and Merck, Gilead's strategic advancements position its HIV franchise for sustainable long-term expansion, though near-term profitability faces pressure from acquisition-related costs.

Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?

https://www.theglobeandmail.com/investing/markets/stocks/GSK/pressreleases/8807259/can-gilead-sciences-hiv-business-fuel-sustainable-long-term-growth/
Gilead Sciences' HIV franchise, led by Biktarvy and Descovy, continues to demonstrate strong performance, with Biktarvy holding over 53% of the U.S. treatment market. The company's new twice-yearly injectable, Yeztugo, is emerging as a key growth driver, supported by high patient adherence and projected to generate $1 billion in full-year sales. Gilead is also advancing a robust HIV pipeline, including potential once-weekly oral and long-acting injectable treatments, which are expected to expand its market presence and contribute to long-term growth despite competition.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement